Next Article in Journal
ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer
Next Article in Special Issue
Potential Therapeutic Significance of Laminin in Head and Neck Squamous Carcinomas
Previous Article in Journal
Mutational Signatures Driven by Epigenetic Determinants Enable the Stratification of Patients with Gastric Cancer for Therapeutic Intervention
Previous Article in Special Issue
Integrin α3β1 Promotes Invasive and Metastatic Properties of Breast Cancer Cells through Induction of the Brn-2 Transcription Factor
Review

Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

1
The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia
2
St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2052, Australia
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2021, 13(3), 491; https://doi.org/10.3390/cancers13030491
Received: 26 November 2020 / Revised: 20 January 2021 / Accepted: 22 January 2021 / Published: 27 January 2021
To improve efficacy of solid cancer treatment, efforts have shifted towards targeting both the cancer cells and the surrounding tumour tissue they grow in. The lysyl oxidase (LOX) family of enzymes underpin the fibrotic remodeling of the tumour microenvironment to promote both cancer growth, spread throughout the body and modulate response to therapies. This review examines how the lysyl oxidase family is involved in tumour development, how they can be targeted, and their potential as diagnostic and prognostic biomarkers in solid tumours.
The lysyl oxidase (LOX) family of enzymes are a major driver in the biogenesis of desmoplastic matrix at the primary tumour and secondary metastatic sites. With the increasing interest in and development of anti-stromal therapies aimed at improving clinical outcomes of cancer patients, the Lox family has emerged as a potentially powerful clinical target. This review examines how lysyl oxidase family dysregulation in solid cancers contributes to disease progression and poor patient outcomes, as well as an evaluation of the preclinical landscape of LOX family targeting therapeutics. We also discuss the suitability of the LOX family as a diagnostic and/or prognostic marker in solid tumours. View Full-Text
Keywords: lysyl oxidases; extracellular matrix; cancer; tumour microenvironment; tumorigenesis; anti-stromal targeting lysyl oxidases; extracellular matrix; cancer; tumour microenvironment; tumorigenesis; anti-stromal targeting
Show Figures

Figure 1

MDPI and ACS Style

Setargew, Y.F.I.; Wyllie, K.; Grant, R.D.; Chitty, J.L.; Cox, T.R. Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours. Cancers 2021, 13, 491. https://doi.org/10.3390/cancers13030491

AMA Style

Setargew YFI, Wyllie K, Grant RD, Chitty JL, Cox TR. Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours. Cancers. 2021; 13(3):491. https://doi.org/10.3390/cancers13030491

Chicago/Turabian Style

Setargew, Yordanos F.I., Kaitlin Wyllie, Rhiannon D. Grant, Jessica L. Chitty, and Thomas R. Cox. 2021. "Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours" Cancers 13, no. 3: 491. https://doi.org/10.3390/cancers13030491

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop